The global continuous renal replacement therapy (CRRT) market was valued at $1.4 billion in 2023 and is expected to reach $2.1 billion by 2028, growing at a compound annual growth rate of 8.1%, according to a new report published by MarketsandMarkets. The market growth is largely driven by factors like the increasing prevalence of acute kidney injury (AKI), rising number of ICU patients with AKI, and increasing cases of sepsis around the world.

The report highlights that AKI cases are increasing rapidly worldwide. For example, the International Society of Nephrology estimates that around 13.3 million AKI cases are recorded globally every year. As the number of elderly people grows, the incidence of kidney diseases is also expected to rise considerably, further contributing to the steady growth of the CRRT market during the next 5 years.

CRRT is an extracorporeal blood purification therapy used in ICU settings to treat patients with severe acute kidney injury or fluid overload that does not respond to conventional therapy. It incorporates various techniques like hemofiltration, hemodialysis, and hemodiafiltration applied in a continuous, slow, and prolonged manner rather than intermittently.

Among the product segments, the dialysates and replacement fluids category is projected to hold the largest market share over the forecast period, driven by the high demand for removing waste products and maintaining electrolyte and acid-base balance in patients undergoing CRRT procedures.

Based on modality, continuous venovenous hemodiafiltration (CVVHDF) is likely to register the highest CAGR owing to its ability to combine ultrafiltration with solute clearance by diffusion and convection, making it effective for patients with acute renal failure or fluid overload.

By age group, the adult segment accounted for the largest revenue share in 2022 due to the higher CRRT adoption among the adult population suffering from acute renal dysfunction. The segment will retain its lead through 2028. On the other hand, the usage of CRRT in pediatrics/neonates will exhibit the highest growth rate.

Among end users, hospitals hold the leading position in terms of market share as CRRT is primarily performed in the critical care units. However, the demand for CRRT in home care settings and ambulatory surgical centers is set to grow at a rapid pace over the coming years.

In 2023, North America is the most prominent regional market for CRRT therapy. Factors such as the high burden of AKI, established presence of major market players, new product approvals, and government's increasing focus on renal care are anticipated to further consolidate North America's market leadership during the forecast period.

Some of the key companies operating in the global CRRT market are Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, and B. Braun Melsungen AG. These players are increasingly investing in developing and launching advanced and cost-effective CRRT systems and solutions to gain an edge in the market.

Overall, with the rising cases of acute renal disorders across the globe, the report projects robust growth prospects for the CRRT market over the next 5 years.